The Online Investor
Foamix Pharmaceuticals Ltd. (FOMX)

Foamix Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on developing and commercializing Co.'s proprietary topical drug candidates for dermatological therapy. Co.'s main product candidate, FMX101 (4% minocycline foam), is being developed for the treatment of moderate-to-severe acne and its second product candidate, FMX103 (1.5% minocycline foam), is being developed for the treatment of moderate-to-severe papulopustular rosacea. Both product candidates are topical foam formulations of the antibiotic minocycline and were developed using its Molecule Stabilizing Technology, a proprietary foam platform designed to optimize the topical delivery of minocycline.
Company Name: 
Foamix Pharmaceuticals Ltd.
Website: 
www.foamix.co.il
Sector: 
Drugs & Pharmaceuticals
Quotes delayed 20 minutes

Email EnvelopeFree FOMX Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Strong Buy (4.00 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Foamix Pharmaceuticals Ltd. (FOMX) Page | The Online Investor Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2024, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.